Opdivo – Education

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma

PRINCETON, N.J.–(BUSINESS WIRE) October 2, 2020 — Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg every three weeks plus Yervoy (ipilimumab) 1 mg/kg every six weeks (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult patients with unresectable malignant pleural… Read More »

Bristol Myers Squibb’s Opdivo cuts relapse risk in muscle-invasive bladder cancer

Bristol Myers Squibb’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease. The company revealed Thursday that its PD-1 fighter, against placebo, had lengthened the time muscle-invasive urothelial carcinoma patients could remain disease-free after surgery. All patients saw benefit,… Read More »